Inhibition of p53 protein aggregation as a cancer treatment strategy

Area of Science:

• Molecular Biology
• Oncology
• Protein Chemistry

Background:

• The p53 protein is a critical tumor suppressor involved in preventing genome mutations.
• Mutations in p53 are common in cancer, leading to pathway malfunction.
• Mutant p53 proteins can lose activity, unfold, and form amyloid aggregates.

Purpose of the Study:

• To review recent advances in strategies aimed at restoring normal p53 expression and activity.
• To detail developments in small-molecule stabilization of mutant p53 protein.
• To discuss the design of inhibitors targeting p53 aggregation.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of small-molecule compounds targeting mutant p53.
• Examination of strategies for inhibiting p53 protein aggregation.

Main Results:

• Emerging small molecules show promise in stabilizing mutant p53 protein.
• Novel inhibitors are being developed to prevent the aggregation of mutant p53.
• These approaches aim to restore the tumor-suppressive function of p53.

Conclusions:

• Targeting mutant p53 stabilization and aggregation represents a promising therapeutic strategy in cancer.
• Further research into small-molecule modulators could lead to new cancer treatments.
• Restoring p53 pathway function is a key goal in oncology research.